Turning Point Therapeutics to Host Conference Call to Discuss Presentations at 2020 EORTC-NCI-AACR Virtual Symposium
Turning Point Therapeutics (NASDAQ: TPTX) has announced a conference call on October 24, 2020, at 11:00 a.m. ET to discuss initial data from its ongoing Phase 1 SHIELD-1 trial of TPX-0022, targeting MET signaling in cancer treatment. The data will be presented by Dr. David Hong during a late-breaking session at the EORTC-NCI-AACR Virtual Symposium. TPX-0022 is evaluated for safety and efficacy in patients with advanced solid tumors. The call can be accessed via the company's website or by phone.
- None.
- None.
Discussion to Include Initial Phase 1 Data from Ongoing SHIELD-1Trial of TPX-0022
SAN DIEGO, Oct. 22, 2020 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today announced it will host a conference call and webcast on Sat., Oct. 24 at 11:00 a.m. ET to discuss its presentations at the 2020 EORTC-NCI-AACR Virtual Symposium, including initial clinical data from the dose finding portion of the Phase 1 SHIELD-1 study of drug candidate, TPX-0022, a potent inhibitor of MET and the associated cancer signaling pathways of SRC and CSF1R.
President and CEO Athena Countouriotis, M.D., will host the webcast and conference call, and will be joined by Turning Point Chief Medical Officer, Mohammad Hirmand, M.D., and David Hong, M.D., Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center.
The audio webcast and accompanying slide presentation will be accessible via the "Investors" section of www.tptherapeutics.com or audio only by dialing (877) 388-2118 (in the United States) or (470) 495-9489 (outside the U.S.) using conference ID 8655648. A replay will be available through the "Investors" section of www.tptherapeutics.com.
The TPX-0022 data are scheduled to be presented earlier that day by Dr. Hong in a late-breaking oral presentation during the plenary session of the Molecular Targets and Cancer Therapeutics virtual symposium hosted by the European Organisation for Research and Treatment of Cancer (EORTC), the National Cancer Institute (NCI) and the American Association for Cancer Research (AACR).
Late-Breaking Presentation Details:
Presentation Title: First-in-human safety, pharmacokinetics, and preliminary efficacy of TPX-0022, a novel inhibitor of MET/SRC/CSF1R in patients with advanced solid tumors harboring genetic alterations in MET
Session Title: Plenary Session 1, Late Breaking and Best Proffered Papers
Presentation Date (Time): Saturday, 24 October 2020 (16:05 - 16:15 CET/10:05 a.m. ET-10:15 a.m. ET)
Presenter: David Hong, M.D., Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center
Presentation Number: 1LBA
About Turning Point Therapeutics Inc.
Turning Point Therapeutics is a clinical-stage precision oncology company with a pipeline of internally discovered investigational drugs designed to address key limitations of existing cancer therapies. The company’s lead drug candidate, repotrectinib, is a next-generation kinase inhibitor targeting the ROS1 and TRK oncogenic drivers of non-small cell lung cancer and advanced solid tumors. Repotrectinib, which is being studied in a registrational Phase 2 study in adults and a Phase 1/2 study in pediatric patients, has shown antitumor activity and durable responses among kinase inhibitor treatment-naïve and pre-treated patients. The company’s pipeline of drug candidates also includes TPX-0022, targeting MET, CSF1R and SRC, which is being studied in the Phase 1 SHIELD-1 trial of patients with advanced or metastatic solid tumors harboring genetic alterations in MET; TPX-0046, targeting RET and SRC, which is being studied in a Phase 1/2 trial of patients with advanced or metastatic solid tumors harboring genetic alterations in RET; and TPX-0131, a next-generation ALK inhibitor in IND-enabling studies. Turning Point’s next-generation kinase inhibitors are designed to bind to their targets with greater precision and affinity than existing therapies, with a novel, compact structure that has demonstrated an ability to potentially overcome treatment resistance common with other kinase inhibitors. The company is driven to develop therapies that mark a turning point for patients in their cancer treatment. For more information, visit www.tptherapeutics.com.
Forward Looking Statements
Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Words such as “plans”, “will”, “believes,” “anticipates,” “expects,” “intends,” “goal,” “potential” and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon Turning Point Therapeutics’ current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, risks and uncertainties associated with Turning Point Therapeutics’ business in general, risks and uncertainties related to the impact of the COVID-19 pandemic to Turning Point’s business and the other risks described in Turning Point Therapeutics’ filings with the SEC. All forward-looking statements contained in this press release speak only as of the date on which they were made. Turning Point Therapeutics undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.
Contact:
Jim Mazzola
jim.mazzola@tptherapeutics.com
858-342-8272
FAQ
What is TPX-0022 and its significance for TPTX?
When will Turning Point Therapeutics present TPX-0022 data?
Who is presenting the data on TPX-0022?
How can I access the conference call about TPTX's TPX-0022?
What time will TPX-0022 data be presented on October 24, 2020?
